美国早期阿尔茨海默病中阿杜那单抗与多奈单抗的成本效果
该决策分析模型评估美国早期阿尔茨海默病患者终身健康与经济结局,比较标准治疗、阿杜那单抗和多奈单抗。阿杜那单抗和多奈单抗相对标准治疗的医疗部门ICER分别为981000美元/QALY和193000美元/QALY;按当前预期价格,两者均不具有成本效果。
要点
- 多奈单抗终身QALY增加0.408,阿杜那单抗增加0.133。
- 阿杜那单抗医疗部门ICER为981000美元/QALY,多奈单抗为193000美元/QALY。
- 按当前预期价格,两者对早期阿尔茨海默病均不具成本效果。
核心结论
- 研究结果表明,按当前预期价格,阿杜那单抗和多奈单抗对美国早期阿尔茨海默病均不具有成本效果。
研究设计与样本
- 决策分析模型,从美国医疗部门和社会视角估算早期阿尔茨海默病成人终身健康与经济结局。
- 模拟患者平均(SD)年龄75.2(5.5)岁,65%为轻度认知障碍,35%为轻度痴呆。
- 分析于2021年4月6日至2022年1月20日进行。
主要发现
- 阿杜那单抗终身QALY增加0.133,多奈单抗增加0.408。
- 阿杜那单抗使医疗部门成本增加130100美元、社会成本增加127800美元;多奈单抗分别增加78700美元和71600美元。
- 阿杜那单抗医疗部门和社会ICER分别为981000美元/QALY和964000美元/QALY;多奈单抗分别为193000美元/QALY和176000美元/QALY。
- 敏感性分析中,即使假设疾病进展减少90%,阿杜那单抗的价值基础价格仍低于50000美元/年。
- 多奈单抗疗效超过50%后,其价值基础价格超过50000美元/年。
关键数值与推荐
- 成本效果阈值定义为ICER 150000美元/QALY。
- 阿杜那单抗选用输入包括疾病进展HR 0.89(95%CI,0.63-1.15)、年价格28000美元、每年两次脑MRI监测。
- 多奈单抗选用输入包括疾病进展HR 0.68(95%CI,0.44-0.99)、年价格28000美元、每年两次脑MRI和淀粉样蛋白PET监测。
- 多奈单抗在PET显示淀粉样蛋白大幅减少后转为安慰剂,6个月时27%患者、12个月时55%患者发生此转换。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Several anti-amyloid monoclonal antibodies have been developed for slowing the progression of Alzheimer disease (AD). Among the furthest developed are aducanumab, which received accelerated approval from the US Food and Drug Administration in 2021, and donanemab, which is currently undergoing phase 3 trials. The cost-effectiveness of these treatments has not been established. OBJECTIVES: To estimate the cost-effectiveness of aducanumab and donanemab relative to standard care for early AD in the US. DESIGN, SETTING, AND PARTICIPANTS: A decision analytic model was used to estimate the lifetime health and economic outcomes of adults with early AD, from US healthcare sector and societal perspectives. Simulated patients had a mean (SD) age of 75.2 (5.5) years; 65% had mild cognitive impairment and 35% had mild dementia. Analyses were conducted from April 6, 2021, to January 20, 2022. INTERVENTIONS: Standard care, aducanumab (selected inputs including disease progression hazard ratio [HR] of 0.89 [95% CI, 0.63-1.15], annual price of $28 000, and twice-yearly monitoring with magnetic resonance imaging [MRI] of the brain), or donanemab (selected inputs including disease progression HR of 0.68 [95% CI, 0.44-0.99], annual price of $28 000, and twice-yearly monitoring with MRI of the brain and amyloid positron emission tomography [PET] monitoring). Donanemab was switched to placebo after substantial amyloid reduction on PET imaging, which occurred in 27% of patients at 6 months and 55% of patients at 12 months. MAIN OUTCOMES AND MEASURES: Quality-adjusted life-years (QALYs); costs, in 2020 US dollars; incremental cost-effectiveness ratios (ICERs); and value-based prices, defined as the maximum price at which a treatment would be cost-effective given a cost-effectiveness threshold of ICER of $150 000/QALY. RESULTS: Lifetime QALYs increased by 0.133 with aducanumab and 0.408 with donanemab. Total health care sector and societal costs increased by $130 100 and $127 800, respectively, with aducanumab and by $78 700 and $71 600, respectively, with donanemab, driven largely by drug costs ($119 000 for aducanumab and $44 600 for donanemab). Health care sector and societal ICERs relative to standard care were $981 000/QALY and $964 000/QALY, respectively, for aducanumab and $193 000/QALY and $176 000/QALY, respectively, for donanemab. In sensitivity analysis, aducanumab's value-based price remained less than $50 000/y, even when assuming a 90% reduction in disease progression. Donanemab's value-based price surpassed $50 000/y once its efficacy exceeded 50%. CONCLUSIONS AND RELEVANCE: These findings suggest that at current expected prices, neither aducanumab nor donanemab would be cost-effective for early AD in the US. Donanemab's dosing scheme, in which patients suspend treatment on achieving substantial amyloid reductions, may provide a rubric by which sufficiently effective anti-amyloid antibody treatments could be cost-effective even when priced comparably to other biologics.
引用
- Ross EL, Weinberg MS, Arnold SE, et al. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US. JAMA Neurol. 2022. PMID: 35344024. doi:10.1001/jamaneurol.2022.0315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。